Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$27,000.00
Identification and Targeting Hypoxia-Driven Metabolic Effectors of Immunosuppression in the Pancreatic Tumour Microenvironment
FY 2024-25
Summary
Pancreatic ductal adenocarcinoma (PDAC) is a difficult-to-treat cancer with poor patient outcomes. This is partially driven by its unique tumour microenvironment (TME), which resists immune attack and protects cancer cells from immunotherapy. The hypoxic (low oxygen) nature of the TME stimulates PDAC cells to undergo metabolic alterations and express proteins such as carbonic anhydrase IX (CAIX), monocarboxylate transporter 4 (MCT4), and cluster of differentiation 39/73 (CD39/73), which acidify the environment and generate immunosuppressive metabolites such as adenosine. These alterations create an immune-cold environment that keeps immune cells, especially T-cells, from fighting PDAC effectively. However, a clear understanding of how these metabolites are distributed within PDAC tumours and how immune cells are affected by and respond to them is still lacking. This project aims to decipher how PDAC cells that upregulate hypoxia-induced proteins produce metabolites that hinder T-cell function and contribute to immune suppression in PDAC. Mass spectrometry and mass spectrometry imaging techniques will identify and visualize known and novel metabolites and their spatial distribution within the PDAC TME. Changes in the distribution and levels of these metabolites after inhibiting CAIX, MCT4 and CD39/73, as well as their impact on the immune contexture, will be assessed through co-culturing experiments with patient-derived PDAC cells and T-cells. By understanding how hypoxic PDAC cells create an immune-resistant TME, this project will reveal metabolic targets susceptible to therapeutic intervention and will guide new strategies to enhance immunotherapy for PDAC. This project ultimately aims to improve PDAC patient outcomes worldwide.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529686
Name
Ristic Ivan
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification and Targeting Hypoxia-Driven Metabolic Effectors of Immunosuppression in the Pancreatic Tumour Microenvironment
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acidosis; Caix; Cd39/73; Extracellular Adenosine; Hypoxia; Immunosuppression; Mass Spectrometry Imaging; Mct4; Metabolomics; Pancreatic Ductal Adenocarcinoma (Pdac)
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a difficult-to-treat cancer with poor patient outcomes. This is partially driven by its unique tumour microenvironment (TME), which resists immune attack and protects cancer cells from immunotherapy. The hypoxic (low oxygen) nature of the TME stimulates PDAC cells to undergo metabolic alterations and express proteins such as carbonic anhydrase IX (CAIX), monocarboxylate transporter 4 (MCT4), and cluster of differentiation 39/73 (CD39/73), which acidify the environment and generate immunosuppressive metabolites such as adenosine. These alterations create an immune-cold environment that keeps immune cells, especially T-cells, from fighting PDAC effectively. However, a clear understanding of how these metabolites are distributed within PDAC tumours and how immune cells are affected by and respond to them is still lacking. This project aims to decipher how PDAC cells that upregulate hypoxia-induced proteins produce metabolites that hinder T-cell function and contribute to immune suppression in PDAC. Mass spectrometry and mass spectrometry imaging techniques will identify and visualize known and novel metabolites and their spatial distribution within the PDAC TME. Changes in the distribution and levels of these metabolites after inhibiting CAIX, MCT4 and CD39/73, as well as their impact on the immune contexture, will be assessed through co-culturing experiments with patient-derived PDAC cells and T-cells. By understanding how hypoxic PDAC cells create an immune-resistant TME, this project will reveal metabolic targets susceptible to therapeutic intervention and will guide new strategies to enhance immunotherapy for PDAC. This project ultimately aims to improve PDAC patient outcomes worldwide.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ristic, Ivan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~